Finance

Lists
TNXP:NASDAQ
Tonix Pharmaceuticals Holding Corp
US$8,02
-0,62%
(-0,050) 1D
6 ຕ.ລ., 12 ໂມງ 26 ນາທີ 48 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TNXP...
Open
US$8,15
High
US$8,33
Low
US$7,69
Mkt. cap
151,87 ລ້ານ
Avg. vol.
499,62 ພັນ
Volume
1,92 ລ້ານ
52-wk high
US$24,49
52-wk low
US$7,69
EPS
US$-12,92
Beta
1,78
Shares outstanding
17,15 ລ້ານ
No. of employees
142
Open
US$8,15
High
US$8,33
Low
US$7,69
Mkt. cap
151,87 ລ້ານ
Avg. vol.
499,62 ພັນ
Volume
1,92 ລ້ານ
52-wk high
US$24,49
52-wk low
US$7,69
EPS
US$-12,92
Beta
1,78
Shares outstanding
17,15 ລ້ານ
No. of employees
142
News stories
From web sources and news partners
Profile
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project. Wikipedia
About Tonix Pharmaceuticals Holding Corp
CEOSeth Lederman
Employees142
Founded2007
HeadquartersBerkeley Heights, ນິວເຈີຊີ, ສະຫະລັດ
SectorBiotechnology
Analyst ratings
Based on 3 analysts giving stock ratings to TNXP in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for TNXP in the last 3 months.
Highest
Current US$8,02
US$65,00 (+710,47%)
Average
US$38,00 (+373,82%)
Lowest
US$22,00 (+174,31%)
Analyst
Recommendation
Action
Price target
Projected
Date
James Molloy
Alliance Global Partners
Buy
Reiterated
US$65,00
+710,5%
09/28/2026
Stacy Ku
TD Cowen
Buy
Maintained
US$22,00
+174,3%
08/10/2026
Tiago Fauth
Raymond James
Buy
Reiterated
US$27,00
+236,7%
08/10/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
US$37,00
+361,3%
03/16/2026
Last report
10 ສ.ຫ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
US$-2,47 / US$-2,62
+5,58%beat
Revenue / Est. (USD)
13,54 ລ້ານ / 7,72 ລ້ານ
+75,38%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
3,29 ລ້ານ
5,39 ລ້ານ
6,88 ລ້ານ
13,54 ລ້ານ
Cost of goods sold
1,37 ລ້ານ
1,06 ລ້ານ
1,58 ລ້ານ
703,00 ພັນ
Cost of revenue
1,37 ລ້ານ
1,06 ລ້ານ
1,58 ລ້ານ
703,00 ພັນ
Research and development expenses
9,29 ລ້ານ
16,94 ລ້ານ
18,21 ລ້ານ
19,42 ລ້ານ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
25,70 ລ້ານ
35,68 ລ້ານ
28,62 ລ້ານ
35,96 ລ້ານ
Operating expense
34,99 ລ້ານ
52,62 ລ້ານ
46,84 ລ້ານ
55,38 ລ້ານ
Total operating expenses
36,36 ລ້ານ
53,68 ລ້ານ
48,42 ລ້ານ
56,08 ລ້ານ
Operating income
-33,07 ລ້ານ
-48,29 ລ້ານ
-41,54 ລ້ານ
-42,54 ລ້ານ
Other non operating income
-174,00 ພັນ
32,00 ພັນ
-3,00 ພັນ
551,00 ພັນ
EBT including unusual items
-32,01 ລ້ານ
-46,91 ລ້ານ
-40,19 ລ້ານ
-40,55 ລ້ານ
EBT excluding unusual items
-32,01 ລ້ານ
-46,91 ລ້ານ
-40,19 ລ້ານ
-40,55 ລ້ານ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-32,01 ລ້ານ
-46,91 ລ້ານ
-40,19 ລ້ານ
-40,55 ລ້ານ
Net profit margin
-972,95%
-870,32%
-584,38%
-299,41%
Earnings per share
-3,70
-3,98
-2,93
-2,47
Interest and investment income
1,23 ລ້ານ
1,34 ລ້ານ
1,35 ລ້ານ
1,43 ລ້ານ
Interest expense
-
-
-
-
Net interest expenses
1,23 ລ້ານ
1,34 ລ້ານ
1,35 ລ້ານ
1,43 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
-32,61 ລ້ານ
-47,80 ລ້ານ
-40,98 ລ້ານ
-41,92 ລ້ານ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
ແອັບຂອງ Google